The AR Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the androgen receptor (AR) gene in a human lung adenocarcinoma model. This polyclonal knockout product provides a heterogeneous pool of gene-disrupted A-549 cells, enabling robust functional genomics investigations without single-cell clone isolation. The cell population is generated via CRISPR/Cas9-mediated gene disruption, offering a valuable tool for dissecting AR-dependent signaling networks in an epithelial lung cancer context.
The host cell line A-549 is a well-characterized adherent epithelial cell line derived from human lung adenocarcinoma tissue of a 58-year-old male. These cells exhibit alveolar type II epithelial-like properties and are widely employed as a model system for studying lung adenocarcinoma biology, drug responses, and oncogenic signaling pathways. The availability of AR knockout polyclonal cells in this background allows researchers to interrogate the specific contributions of androgen receptor signaling to lung cancer cell behavior without confounding effects from endogenous wild-type AR expression.
AR encodes a ligand-dependent nuclear hormone receptor that functions as a transcription factor mediating androgen signaling. Upon binding of androgens such as dihydrotestosterone, AR dissociates from heat shock proteins HSP90 and HSP70, translocates to the nucleus, dimerizes, and binds to androgen response elements (AREs) to regulate target gene expression. Its activity is modulated through crosstalk with growth factor pathways, where upstream kinases including SRC, AKT, and MAPK1 phosphorylate AR, influencing its transcriptional output. Key downstream targets include KLK3 (PSA), TMPRSS2, FKBP5, and NKX3-1, while transcriptional coactivators such as NCOA1 (SRC-1) and NCOA2 (TIF2), and pioneer factors FOXA1 and GATA2, facilitate AR binding to chromatin. AR signaling intersects with MAPK/ERK, PI3K/AKT, Wnt, TGF-beta, and JAK/STAT pathways, highlighting its integrative role in cellular proliferation and survival.
In the A-549 lung adenocarcinoma context, AR knockout polyclonal cells enable dissection of androgen signaling contributions to lung cancer pathogenesis. Although AR is most studied in prostate cancer, emerging evidence implicates androgen signaling in lung adenocarcinoma progression, epithelial-mesenchymal transition (EMT), and therapeutic resistance. This model permits evaluation of AR-dependent gene expression programs and crosstalk with oncogenic pathways. By eliminating AR, researchers can assess impacts on proliferation, migration, invasion, and responses to anti-androgen therapies, linking androgen receptor activity to lung cancer phenotypes.
Typical applications of this product include quantitative transcriptional profiling of AR target genes via RT-qPCR and RNA-seq, protein analysis by Western blotting and immunofluorescence, and functional assays using ARE-luciferase reporters. The polyclonal knockout cells are suitable for drug sensitivity testing, colony formation assays, and apoptosis and migration/invasion studies. These applications support research into androgen signaling crosstalk, EMT mechanisms, and drug resistance in lung adenocarcinoma. For further information on product specifications, validation, and ordering, please contact Ascent Research.
